title: Serum ischemia modified albumin and vascular endothelial growth factor levels following intravitreal bevacizumab injections.
abstract: OBJECTIVE
  Previous reports have demonstrated that the serum levels of vascular endothelial growth factor (VEGF) are reduced after intravitreal injections of bevacizumab. This study aimed to determine the serum levels of ischemia-modified albumin (IMA), a marker of ischemia, and VEGF following intravitreal injections of bevacizumab.
  
  
  METHODS
  This was a prospective study. Blood samples were drawn prior to injection and at 1, 7, and 30 days after injection.
  
  
  RESULTS
  A total of 11 patients participated in this study. Mean serum IMA levels were lower than baseline during follow-up, with statistically significant differences compared to baseline levels at day 1 and day 30 (preinjection: 49.82 ± 15.28 ng/mL; 44.57 ± 12.01 ng/mL, p = 0.007, and 43.71 ± 13.82 ng/mL, p = 0.001, respectively). Mean serum VEGF levels were lower than baseline throughout the follow-up period (from 307.45 ± 273.45 pg/mL at baseline to 159.55 ± 120.68 pg/mL at day 30). Mean serum VEGF levels were significantly lower compared to baseline levels at day 1 and day 7 (147.09 ± 106.08 pg/mL, p = 0.014; 72.91 ± 50 pg/mL, p = 0.011, respectively).
  
  
  CONCLUSIONS
  In this study, mean serum IMA and VEGF levels were lower following intravitreal bevacizumab injections.
authors: Department of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv - Israel.
authors: Uri
authors: U
authors: Soiberman
authors: Ran
authors: R
authors: Levy
authors: Shulamit
authors: S
authors: Schwartz
authors: Michaella
authors: M
authors: Goldstein
authors: Anat
authors: A
authors: Loewenstein
authors: Adiel
authors: A
authors: Barak
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D015415:Biomarkers / Q000097:blood; D003930:Diabetic Retinopathy / Q000097:blood / Q000188:drug therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000097:blood / Q000188:drug therapy; D008269:Macular Edema / Q000097:blood / Q000188:drug therapy; D008297:Male; D011446:Prospective Studies; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000097:blood*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D012709:Serum Albumin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C561522:ischemia-modified albumin; D000068258:Bevacizumab; D000075462:Serum Albumin, Human